Sanofi Consumer Healthcare India reported a 21.78% rise in quarterly profit after tax. LiveMint reported an intraday high of ₹3,771.90, which was 13.5% above the previous close based on the prices it cited.
For the three months through Sept. 30, revenue from operations totaled ₹2,631 million, compared with ₹2,339 million a year earlier, the company’s unaudited results showed. Profit after tax was ₹766 million, up from ₹629 million. Profit before tax increased to ₹1,027 million from ₹841 million.
Domestic sales grew 19% during the quarter. Sanofi linked the performance to higher volumes and market-share gains across several leading brands. It also cited spending on brand promotion, distribution and engagement with health professionals. Managing Director Himanshu Bakshi said the quarter reflected “the strength of our portfolio.”
Across the first nine months of 2026, revenue from operations rose 16% to ₹7,280 million. Sanofi said domestic sales gained 15%, with product relaunches supporting growth. Export sales increased 19%, while profit before tax rose 24% over the period.
In its Oct. 29 report, LiveMint put the session’s high at ₹3,771.90, with an opening price of ₹3,502.20 and an Oct. 28 previous close of ₹3,322.80. The reported high was 13.5% above that close based on those prices, although LiveMint characterized the increase as 11%.
Trendlyne lists a ₹5,855 consensus target based on one analyst report dated Oct. 20, before Sanofi released its results. The page does not show a post-results update or explain the target’s rationale.
